1. Home
  2. FSP vs GANX Comparison

FSP vs GANX Comparison

Compare FSP & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Franklin Street Properties Corp.

FSP

Franklin Street Properties Corp.

HOLD

Current Price

$0.63

Market Cap

72.4M

Sector

Real Estate

ML Signal

HOLD

Logo Gain Therapeutics Inc.

GANX

Gain Therapeutics Inc.

HOLD

Current Price

$1.75

Market Cap

78.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FSP
GANX
Founded
1981
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
72.4M
78.2M
IPO Year
2001
2021

Fundamental Metrics

Financial Performance
Metric
FSP
GANX
Price
$0.63
$1.75
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$7.50
AVG Volume (30 Days)
552.7K
707.7K
Earning Date
04-28-2026
05-13-2026
Dividend Yield
6.34%
N/A
EPS Growth
15.69
31.46
EPS
N/A
N/A
Revenue
$107,162,000.00
$55,180.00
Revenue This Year
$17.91
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.50
$1.41
52 Week High
$1.82
$4.34

Technical Indicators

Market Signals
Indicator
FSP
GANX
Relative Strength Index (RSI) 55.65 47.09
Support Level $0.58 $1.66
Resistance Level $0.70 $2.12
Average True Range (ATR) 0.06 0.12
MACD 0.02 -0.01
Stochastic Oscillator 51.01 36.73

Price Performance

Historical Comparison
FSP
GANX

About FSP Franklin Street Properties Corp.

Franklin Street Properties Corp is a real estate investment trust. The company is focused on commercial real estate investments in office markets and currently operate in only one segment: real estate operations. The principal revenue sources for its real estate operations include rental income from real estate leasing, property dispositions and fee income from asset/property management and development. The company provides asset management, property management, property accounting, investor and/or development services to its portfolio and Sponsored REIT through the company's subsidiaries.

About GANX Gain Therapeutics Inc.

Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.

Share on Social Networks: